PTC Therapeutics Inc
F:P91
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PTC Therapeutics Inc
F:P91
|
US |
|
I
|
Interpublic Group of Companies Inc
F:IPG
|
US |
|
A
|
Alexandria Real Estate Equities Inc
F:A6W
|
US |
|
Post Holdings Inc
NYSE:POST
|
US |
|
JCDecaux SE
F:DCS0
|
FR |
|
K
|
Konami Holdings Corp
LSE:KNM
|
JP |
Wall St Price Targets
P91 Price Targets Summary
PTC Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for P91 is 48.13 EUR with a low forecast of 34.07 EUR and a high forecast of 67.56 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is P91's stock price target?
Price Target
48.13
EUR
According to Wall Street analysts, the average 1-year price target for P91 is 48.13 EUR with a low forecast of 34.07 EUR and a high forecast of 67.56 EUR.
What is the Revenue forecast for PTC Therapeutics Inc?
Projected CAGR
-2%
Over the last 13 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 3 years is -2%.
What is the Gross Profit forecast for PTC Therapeutics Inc?
Projected CAGR
-5%
The compound annual growth rate for Gross Profit over the next 3 years is -5%.
What is the Operating Income forecast for PTC Therapeutics Inc?
Projected CAGR
-12%
The compound annual growth rate for Operating Income over the next 3 years is -12%.
What is the Pre-Tax Income forecast for PTC Therapeutics Inc?
Projected CAGR
-20%
The compound annual growth rate for Pre-Tax Income over the next 3 years is -20%.
What is the Net Income forecast for PTC Therapeutics Inc?
Projected CAGR
-20%
Over the last 13 years, the compound annual growth rate for Net Income has been 70%. The projected CAGR for the next 3 years is -20%.
